3-[3-(3-Bromo-propoxy)-phenyl]-propionic acid ethyl ester | 156005-38-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-[3-(3-Bromo-propoxy)-phenyl]-propionic acid ethyl ester
• 英文别名: Ethyl 3-[3-(3-bromopropoxy)phenyl]propanoate
• CAS: 156005-38-8
• 化学式: C₁₄H₁₉BrO₃
• 分子量: 315.207
• InChiKey: VWKRVQXFYHJDQJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-[3-(3-Bromo-propoxy)-phenyl]-propionic acid ethyl ester 在 potassium carbonate 、 potassium iodide 作用下， 以 丁酮 为溶剂， 反应 74.0h， 生成 3-(3-{3-[4-((Z)-3-Dimethylamino-acryloyl)-2-ethyl-5-hydroxy-phenoxy]-propoxy}-phenyl)-propionic acid ethyl ester
  参考文献：
  名称：

  Leukotriene B4 (LTB4) Receptor Antagonists: A Series of (Hydroxyphenyl)pyrazoles

  摘要：

  A series of (hydroxyphenyl)pyrazoles was designed by molecular modeling comparison with the LTB(4) structure and prepared for evaluation as LTB(4) receptor antagonists, culminating in 4-ethyl-5-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]-2-(1H-pyrazol-3-yl)phenyl (2). Using an assay for inhibition of specific [H-3]LTB(4) binding to human PMN, it was found that the pyrazole ring could be methylated at N(1) with little loss of activity while methylation at N(2) reduced activity significantly. The structure-activity relationship of the terminal acid group was investigated. Good activity was found with o- and m-phenylalkanoic acids, chromane carboxylic acid, and tetrazole groups. The best in vitro activity was realized with the pyrazole nitrogen unsubstituted and with a six-carbon chain linking the phenyl ether oxygen to the tetrazole group. Compound 2, having an IC50 of 6.4 +/- 0.8 nM in the binding assay, was selected for further preclinical evaluation.

  DOI：

  10.1021/jm00041a021
• 作为产物：
  描述：

  3-邻羟基苯基丙酸乙酯 、 1,3-二溴丙烷 在 potassium carbonate 作用下， 以 丁酮 为溶剂， 以21%的产率得到3-[3-(3-Bromo-propoxy)-phenyl]-propionic acid ethyl ester
  参考文献：
  名称：

  Leukotriene B4 (LTB4) Receptor Antagonists: A Series of (Hydroxyphenyl)pyrazoles

  摘要：

  A series of (hydroxyphenyl)pyrazoles was designed by molecular modeling comparison with the LTB(4) structure and prepared for evaluation as LTB(4) receptor antagonists, culminating in 4-ethyl-5-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]-2-(1H-pyrazol-3-yl)phenyl (2). Using an assay for inhibition of specific [H-3]LTB(4) binding to human PMN, it was found that the pyrazole ring could be methylated at N(1) with little loss of activity while methylation at N(2) reduced activity significantly. The structure-activity relationship of the terminal acid group was investigated. Good activity was found with o- and m-phenylalkanoic acids, chromane carboxylic acid, and tetrazole groups. The best in vitro activity was realized with the pyrazole nitrogen unsubstituted and with a six-carbon chain linking the phenyl ether oxygen to the tetrazole group. Compound 2, having an IC50 of 6.4 +/- 0.8 nM in the binding assay, was selected for further preclinical evaluation.

  DOI：

  10.1021/jm00041a021

文献信息

• Leukotriene B4 (LTB4) Receptor Antagonists: A Series of (Hydroxyphenyl)pyrazoles
  作者：Richard W. Harper、William T. Jackson、Larry L. Froelich、Robert J. Boyd、Timothy E. Aldridge、David K. Herron

  DOI：10.1021/jm00041a021

  日期：1994.7

  A series of (hydroxyphenyl)pyrazoles was designed by molecular modeling comparison with the LTB(4) structure and prepared for evaluation as LTB(4) receptor antagonists, culminating in 4-ethyl-5-[[6-methyl-6-(1H-tetrazol-5-yl)heptyl]oxy]-2-(1H-pyrazol-3-yl)phenyl (2). Using an assay for inhibition of specific [H-3]LTB(4) binding to human PMN, it was found that the pyrazole ring could be methylated at N(1) with little loss of activity while methylation at N(2) reduced activity significantly. The structure-activity relationship of the terminal acid group was investigated. Good activity was found with o- and m-phenylalkanoic acids, chromane carboxylic acid, and tetrazole groups. The best in vitro activity was realized with the pyrazole nitrogen unsubstituted and with a six-carbon chain linking the phenyl ether oxygen to the tetrazole group. Compound 2, having an IC50 of 6.4 +/- 0.8 nM in the binding assay, was selected for further preclinical evaluation.